title: Cardiac dysfunction after cancer treatment.
abstract: Onco-cardiology is an evolving discipline that requires the consideration of cardiotoxicity in preclinical, clinical,and therapeutic aspects of protocol development,treatment, and surveillance of patients who have undergone interventions using cardiotoxic agents. Only then can we foster new ways to maximize survival while keeping cardiac damage within acceptable limits. It is to this end that our working together has brought us to our present understanding. In the future, we may expect onco-cardiology to play an even greater role in the care of cancer patients.
authors: Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. mewer@mdanderson.org
authors: Michael S
authors: MS
authors: Ewer
authors: Sandra M
authors: SM
authors: Swain
authors: Daniela
authors: D
authors: Cardinale
authors: Anecita
authors: A
authors: Fadol
authors: Thomas M
authors: TM
authors: Suter
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002309:Cardiology; D003299:Cooperative Behavior; D019033:Delivery of Health Care, Integrated; D006321:Heart / Q000187:drug effects* / Q000503:physiopathology; D006331:Heart Diseases / Q000139:chemically induced* / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D033183:Interdisciplinary Communication; D008495:Medical Oncology; D032383:Myocytes, Cardiac / Q000187:drug effects* / Q000473:pathology; D010348:Patient Care Team; D011379:Prognosis; D018570:Risk Assessment; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents